Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder

BACKGROUND: Overactive bladder (OAB) is defined as urinary urgency accompanied by frequency and nocturia, with or without urge urinary incontinence (UUI). Vibegron, a selective β(3)-adrenergic receptor agonist approved in the US in December 2020, demonstrated efficacy in reducing symptoms of OAB and...

Descripción completa

Detalles Bibliográficos
Autores principales: Dmochowski, Roger R., Rovner, Eric S., Kennelly, Michael J., Newman, Diane K., Abedinzadeh, Laleh, Snyder, Daniel, Thomas, Elizabeth, Haag-Molkenteller, Cornelia, Rosenberg, Matt T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124676/
https://www.ncbi.nlm.nih.gov/pubmed/37095473
http://dx.doi.org/10.1186/s12894-023-01240-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124676/
https://www.ncbi.nlm.nih.gov/pubmed/37095473
http://dx.doi.org/10.1186/s12894-023-01240-7

Ejemplares similares